MYBL2 and ovarian carcinoma: Based on the growth‐promoting activities of B‐MYB in cancer cells as well as on its overexpression and linkage to poor prognosis in multiple malignancies (including cervical cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, non‐small cell lung cancer, and hepatocellular carcinoma) [34, 43, 44, 45, 46, 47, 48], there are intense efforts to generate specific B‐MYB inhibitors and to assess their potential for cancer therapy [20, 49, 50].